<SEC-DOCUMENT>0001104659-25-011845.txt : 20250212
<SEC-HEADER>0001104659-25-011845.hdr.sgml : 20250212
<ACCEPTANCE-DATETIME>20250212080037
ACCESSION NUMBER:		0001104659-25-011845
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250212
DATE AS OF CHANGE:		20250212

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Edesa Biotech, Inc.
		CENTRAL INDEX KEY:			0001540159
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87615
		FILM NUMBER:		25612057

	BUSINESS ADDRESS:	
		STREET 1:		100 SPY COURT
		CITY:			MARKHAM
		STATE:			A6
		ZIP:			L3R 5H6
		BUSINESS PHONE:		(905) 475-1234

	MAIL ADDRESS:	
		STREET 1:		100 SPY COURT
		CITY:			MARKHAM
		STATE:			A6
		ZIP:			L3R 5H6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stellar Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20120120

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SATTERFIELD THOMAS A JR
		CENTRAL INDEX KEY:			0001132317
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		2609 CALDWELL MILL LN
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35243
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-24-067780</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: SATTERFIELD THOMAS A JR -->
          <cik>0001132317</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, without par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001540159</issuerCik>
        <issuerName>Edesa Biotech, Inc.</issuerName>
        <issuerCusip>27966L306</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>100 Spy Court</com:street1>
          <com:city>Markham</com:city>
          <com:stateOrCountry>A6</com:stateOrCountry>
          <com:zipCode>L3R 5H6</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>40247.00</soleVotingPower>
        <sharedVotingPower>191914.00</sharedVotingPower>
        <soleDispositivePower>40247.00</soleDispositivePower>
        <sharedDispositivePower>191914.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>232161.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>6.7</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>* Based on 3,467,658 shares of common stock of the issuer outstanding as of December 11, 2024, as reported by the issuer in its Annual Report on Form 10-K for the fiscal year ended September 30, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Edesa Biotech, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>100 Spy Court, Markham, Ontario, Canada, L3R 5H6</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Thomas A. Satterfield, Jr.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>15 Colley Cove Drive
Gulf Breeze, Florida 32561</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Incorporated by reference from Item 4 of the Cover Page.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Incorporated by reference from Item 9 of the Cover Page.</amountBeneficiallyOwned>
        <classPercent>Incorporated by reference from Item 11 of the Cover Page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Incorporated by reference from Item 5 of the Cover Page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Incorporated by reference from Item 6 of the Cover Page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Incorporated by reference from Item 7 of the Cover Page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Incorporated by reference from Item 8 of the Cover Page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 40,000 shares are held by Tomsat Investment &amp; Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 118,914 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 25,000 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.

Additionally, Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to the following shares: Rebecca A. Satterfield (8,000 shares). Ms. Satterfield has the right to receive or the power to direct the receipt of the proceeds from the sale of her shares.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Thomas A. Satterfield, Jr.</signature>
        <title>Thomas A. Satterfield, Jr.</title>
        <date>02/12/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
